灭活全菌体霍乱疫苗的保护效果:系统综述与Meta分析
该系统综述与Meta分析更新了灭活全菌体口服霍乱疫苗(kOCV)保护效果的证据,纳入5项随机对照试验和10项观察性研究。两剂kOCV接种后12个月平均效力为55%(95%CI 46-62),48个月降至44%(25-59);两剂平均效果12个月为69%(58-78),48个月降至47%(9-70)。一剂kOCV提供至少2年保护但衰减快于两剂,5岁以下儿童保护低于5岁及以上人群。
要点
- 两剂kOCV接种后至少4年内对就医确诊霍乱提供保护。
- 一剂kOCV提供至少2年保护,但保护衰减快于两剂。
- 5岁以下儿童无论接种剂次,保护均低于5岁及以上人群。
核心结论
- 两剂kOCV接种后至少4年内对就医确诊霍乱提供保护。
- 一剂kOCV提供至少2年保护,但衰减快于两剂。
- 5岁以下儿童接种kOCV的保护低于5岁及以上人群,与接种剂次无关。
研究设计与样本
- 系统综述与Meta分析,检索截至2024年3月8日,纳入5项随机对照试验和10项观察性研究(来自23篇文献)。
- 检索策略与既往系统综述相同,纳入报告kOCV对就医确诊霍乱保护估计的随机对照试验和观察性研究。
- 采用随机效应模型分别汇总效力和效果估计,采用Meta回归模型按剂次估计保护随接种后时间的变化。
- 该更新研究与原始综述共同注册于PROSPERO(CRD42016048232)。
主要发现
- 两剂平均效力在接种后12个月为55%(95%CI 46-62),48个月降至44%(25-59)。
- 两剂平均效果在接种后12个月为69%(58-78),48个月降至47%(9-70)。
- 仅一项随机对照试验评估一剂效力,发现5岁及以上人群24个月持续保护为57%(42-69),年幼儿童无显著保护。
- 一剂平均效果在接种后12个月为60%(51-68),24个月为47%(34-58)。
- 年龄组特异性Meta分析发现,5岁以下儿童两剂平均效力为5岁及以上人群的一半。
关键数值与推荐
- 两剂kOCV接种后12个月平均效力55%(95%CI 46-62),48个月44%(25-59)。
- 两剂kOCV接种后12个月平均效果69%(58-78),48个月47%(9-70)。
- 一剂kOCV接种后12个月平均效果60%(51-68),24个月47%(34-58)。
- 5岁及以上人群一剂效力24个月为57%(42-69),年幼儿童无显著保护。
- 5岁以下儿童两剂平均效力为5岁及以上人群的一半。
临床怎么用
- 两剂kOCV可在霍乱流行区及疫情和人道主义紧急情况中作为标准预防控制措施使用。
- 一剂kOCV可提供至少2年保护,但保护衰减快于两剂。
- 5岁以下儿童接种kOCV的保护低于5岁及以上人群,与接种剂次无关。
局限性
- 仅一项随机对照试验评估一剂效力,且该试验发现年幼儿童无显著保护。
- 5岁以下儿童两剂平均效力仅为5岁及以上人群的一半。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Killed whole-cell oral cholera vaccines (kOCVs) are a standard prevention and control measure in cholera-endemic areas and during outbreaks and humanitarian emergencies. New evidence has emerged and the ways in which the vaccines are used have changed. We aimed to provide an updated synthesis of evidence on protection conferred by kOCV. METHODS: In this systematic review and meta-analysis, we used the same search procedure as a previous systematic review to identify randomised clinical trials (RCTs) and observational studies that reported estimates of protection conferred by kOCVs against medically attended, confirmed cholera. Eligible studies in English, French, Spanish, or Chinese published up until March 8, 2024, including those identified in the previous review, were included. Data on efficacy and effectiveness were extracted, as were the number of doses, duration of follow-up, and age group. Efficacy and effectiveness estimates were summarised separately using random-effect models to estimate protection by time since vaccination; meta-regression models were used to estimate protection, by dose, as a function of time since vaccination. This updated study is registered along with the original review with PROSPERO (CRD42016048232). FINDINGS: We identified 8205 records published online up until March 8, 2024, including 6224 articles from the previous review and 1981 articles from our new search (after Jan 1, 2016). Of these, 53 were eligible for full-text review. Five RCTs and ten observational studies from 23 publications were included. Average two-dose efficacy 12 months after vaccination was 55% (95% CI 46-62), declining to 44% (25-59) 48 months after vaccination. Average two-dose effectiveness was 69% (58-78) 12 months after vaccination, declining to 47% (9-70) 48 months after vaccination. Only one RCT assessed one-dose efficacy and found sustained protection for 24 months (57% [42-69]) among those 5 years and older with no significant protection in younger children. Average one-dose effectiveness 12 months after vaccination was 60% (51-68) and after 24 months was 47% (34-58). Using age group-specific meta-analysis, we found that average two-dose efficacy in children younger than 5 years was half that of older individuals. INTERPRETATION: Two doses of kOCV provide protection against medically attended cholera for at least 4 years after vaccination. One dose of kOCV provides protection for at least 2 years after vaccination, but wanes faster than that of two doses. Children younger than 5 years are less protected by kOCVs than those aged 5 years and older, regardless of the number of doses received. FUNDING: Bill & Melinda Gates Foundation.
引用
- Xu H, Tiffany A, Luquero FJ, et al. Protection from killed whole-cell cholera vaccines: a systematic review and meta-analysis. Lancet Glob Health. 2025. PMID: 40580988. doi:10.1016/S2214-109X(25)00107-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。